Egawa S - Search Results

1

Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.

Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, Kimura S, Kimura T, Egawa S, Briganti A, Karakiewicz PI, Shariat SF. Mori K, et al. Among authors: egawa s. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):539-548. doi: 10.1038/s41391-020-0222-6. Epub 2020 Mar 9. Prostate Cancer Prostatic Dis. 2020. PMID: 32152435

2

Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan.

Egawa S, Suyama K, Ohori M, Kawakami T, Kuwao S, Hirokado K, Hirano S, Yokoyama E, Uchida T, Koshiba K. Egawa S, et al. Cancer. 1995 Aug 1;76(3):463-72. doi: 10.1002/1097-0142(19950801)76:3<463::aid-cncr2820760317>3.0.co;2-a. Cancer. 1995. PMID: 8625128

3

The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.

Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, Kuwao S, Koshiba K. Egawa S, et al. Cancer. 1997 Jan 1;79(1):90-8. Cancer. 1997. PMID: 8988731

4

Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.

Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S. Egawa S, et al. Cancer. 1999 Aug 1;86(3):463-9. Cancer. 1999. PMID: 10430254

5

Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml.

Egawa S, Suyama K, Takashima R, Kuwao S, Baba S. Egawa S, et al. Prostate Cancer Prostatic Dis. 2002;5(2):115-8. doi: 10.1038/sj.pcan.4500562. Prostate Cancer Prostatic Dis. 2002. PMID: 12496999

6

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy.

Egawa S, Arai Y, Tobisu K, Kuwao S, Kamoto T, Kakehi Y, Baba S. Egawa S, et al. Prostate Cancer Prostatic Dis. 2000 Dec;3(4):269-274. doi: 10.1038/sj.pcan.4500424. Prostate Cancer Prostatic Dis. 2000. PMID: 12497076

7

Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.

Egawa S, Okusa H, Matsumoto K, Suyama K, Baba S. Egawa S, et al. Prostate Cancer Prostatic Dis. 2003;6(3):245-9. doi: 10.1038/sj.pcan.4500675. Prostate Cancer Prostatic Dis. 2003. PMID: 12970730 Clinical Trial.

8

Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan.

Egawa S, Matsui Y, Matsumoto K, Suyama K, Arai Y, Kuwao S, Baba S. Egawa S, et al. Prostate Cancer Prostatic Dis. 2004;7(2):152-7. doi: 10.1038/sj.pcan.4500715. Prostate Cancer Prostatic Dis. 2004. PMID: 15175664

9

Proteome analysis of prostate cancer.

Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, Maeda T. Kuruma H, et al. Among authors: egawa s. Prostate Cancer Prostatic Dis. 2005;8(1):14-21. doi: 10.1038/sj.pcan.4500764. Prostate Cancer Prostatic Dis. 2005. PMID: 15477873 Review.

10

Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.

Hayashi N, Urashima M, Ikemoto I, Kuruma H, Arai Y, Kuwao S, Baba S, Egawa S. Hayashi N, et al. Among authors: egawa s. Prostate Cancer Prostatic Dis. 2007;10(1):60-5. doi: 10.1038/sj.pcan.4500902. Epub 2006 Oct 3. Prostate Cancer Prostatic Dis. 2007. PMID: 17003775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

980 results

Search Page

Filters